SI-053 Phase 1 Clinical Trial in Germany was approved. The patent for Temodex / SI-053 was granted in Japan at least until the year 2036.
SI-053: the Clinical Trial Application (CTA) was submitted in Germany and the Netherlands. Closter Pharma (Colombia) purchased 3 Temodex vials. A new patent for SA-033 was granted in China, while the patent for Temodex / SI-053 was granted in Mexico at least until the year 2036. SI-053 Phase 1 Clinical Trial in the Netherlands was approved.
The patent for Temodex / SI-053 was granted in 26 European countries, the US and India at least until the year 2036. DBP International AB signed a joint venture agreement with Shijiazhuang Yuanjia Biotechnology (SYB) for Temodex in China. The DBP’s subsidiary FarmPharma started manufacturing the third interferon for the InterferOX product.
A robust preclinical and manufacturing package was designed to better develop SI-053. The clinical department selected a clinical contract research organization. Key Opinion Leaders (KOL) joined the SI-053 trial. Closter Pharma (Colombia) purchased 3 Temodex vials. Inofer (iron succinate): clinical trial was finished.
FarmPharma was established as the second DBP’s subsidiary to develop a novel drug for viral and bacterial infections in livestock. A protocol support application was submitted to the EMA to obtain scientific advice for the development of SI-053. DBP received Eurostars funding from the European Commission to develop a unique treatment for pneumonia based on the BeloGal platform and meropenem with partners from France, Sweden and Cyprus.
SI-053 development entered GLP-certified preclinical phase in Europe. Drugsson was established as our subsidiary to market generics approved in the EU.
DBP received the second orphan drug designation from the EMA – for the treatment of glioblastoma in adults. DBP started the development of SI-053, for the treatment of glioblastoma in Europe. The second international patent family for our self-navigating BeloGal technology was filed.
DBP entered the local stock exchange Aktietorget and became a publicly traded company. Shortly after the IPO, DBP received the first orphan drug designation (ODD) from the EMA for the treatment of pediatric liver cancer, so-called SA-033, based on doxorubicin and our BeloGal technology, SA-033. The first international patent application for BeloGal was filed. DBP also acquired the rights to sell a brain tumor drug from Belarus called Temodex® for global market launch.
Double Bond Pharmaceutical (DBP) was founded in 2014 with the goal of developing and commercializing innovative first-in-class drugs to treat cancer, infections and other life-threatening diseases.